Hepatitis B virus

Hepatitis B virus
Name	Hepatitis B virus
Virus group	Group VII
Familia	Hepadnaviridae
Genus	Orthohepadnavirus
Species	Hepatitis B virus
Synonyms	HBV

Hepatitis B virus is a small, enveloped DNA virus of the family Hepadnaviridae that causes acute and chronic liver infection. The virus is a major global public health concern linked to cirrhosis, hepatocellular carcinoma, and perinatal transmission, and has been the subject of extensive research, public health policy, and vaccine development. Clinical management and control efforts have involved numerous organizations, regulatory agencies, and landmark public health programs.

Virology and Structure

The virion exhibits an outer lipid envelope studded with surface antigens and contains an inner icosahedral nucleocapsid composed of core protein; structural studies have been advanced by groups at Cold Spring Harbor Laboratory, Max Planck Society, National Institutes of Health, European Molecular Biology Laboratory, and Riken. Electron microscopy and cryo-electron microscopy efforts by teams at Howard Hughes Medical Institute, University of Cambridge, Massachusetts Institute of Technology, Stanford University, and University of Oxford clarified particle pleomorphism, comparing Dane particles to subviral particles characterized in work associated with Centers for Disease Control and Prevention, World Health Organization, Imperial College London, University of Tokyo, and Karolinska Institutet. The envelope proteins include small, middle, and large surface antigens; antigenicity studies have informed vaccine design implemented by Gavi, the Vaccine Alliance and surveillance by European Centre for Disease Prevention and Control and Public Health England.

Genome and Replication

The viral genome is a partially double-stranded, relaxed circular DNA with overlapping open reading frames encoding polymerase, core, surface, and X proteins; molecular virology research has been published by scientists affiliated with Harvard University, Yale University, Johns Hopkins University, University of California, San Francisco, and University of Pennsylvania. Reverse transcription of an RNA intermediate (pregenomic RNA) by the viral polymerase parallels mechanisms studied in retrovirology at Cold Spring Harbor Laboratory and comparative genomic analyses by National Center for Biotechnology Information and European Bioinformatics Institute. Host factors from University College London, Pasteur Institute, Weizmann Institute of Science, Seoul National University, and McGill University have been implicated in covalently closed circular DNA formation and persistence, a key obstacle to viral eradication explored in collaborations with Bill & Melinda Gates Foundation–funded initiatives.

Transmission and Epidemiology

Transmission occurs via percutaneous or mucosal exposure to infected blood and body fluids, including vertical transmission during childbirth; epidemiologic patterns have been mapped by World Health Organization, United Nations Children’s Fund, World Bank, African Union, and regional programs such as PAHO and Southeast Asian Regional Office. High-prevalence areas identified in reports from China, Nigeria, India, Philippines, and Indonesia inform screening policies of agencies like Food and Drug Administration, European Medicines Agency, Public Health Agency of Canada, Australian Department of Health, and National Health Service (England). Outbreak investigations have been coordinated with agencies including Médecins Sans Frontières, Red Cross, Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance, and national ministries of health.

Clinical Manifestations and Pathogenesis

Acute infection ranges from asymptomatic seroconversion to icteric hepatitis and fulminant hepatic failure; chronic infection can progress to fibrosis, cirrhosis, and hepatocellular carcinoma, outcomes tracked in cohorts at Memorial Sloan Kettering Cancer Center, Mayo Clinic, Cleveland Clinic, Karolinska University Hospital, and Mount Sinai Health System. The interplay between viral factors (genotype, mutations) and host immune responses has been dissected in studies by National Cancer Institute, Wellcome Trust, Howard Hughes Medical Institute, National Institute for Viral Disease Control and Prevention (China), and university centers such as University of Toronto and University of Hong Kong. Management of liver complications often involves hepatology centers linked to European Association for the Study of the Liver, American Association for the Study of Liver Diseases, Asian Pacific Association for the Study of the Liver, International Liver Cancer Association, and transplant programs at Cleveland Clinic and King’s College Hospital.

Diagnosis and Laboratory Testing

Diagnostic testing relies on serologic markers (surface antigen, e antigen, core antibodies), nucleic acid amplification to quantify viral DNA, and liver function tests; laboratory standards and quality assurance are guided by Clinical and Laboratory Standards Institute, World Health Organization, College of American Pathologists, European Society of Clinical Microbiology and Infectious Diseases, and national reference labs such as Centers for Disease Control and Prevention and Public Health England. Molecular assays developed by industry partners and academic spinouts from Genentech, Roche, Abbott Laboratories, Siemens Healthineers, and Qiagen are used for viral load monitoring and resistance genotyping, while imaging and biopsy protocols involve radiology departments at Mayo Clinic, Massachusetts General Hospital, and Johns Hopkins Hospital.

Prevention and Vaccination

Universal immunization using recombinant hepatitis B vaccines has been promoted by World Health Organization, Gavi, the Vaccine Alliance, UNICEF, Global Fund, and national immunization programs in China, United States, Brazil, South Africa, and India. Vaccine research and policy work has involved collaborations with Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, Bill & Melinda Gates Foundation, PATH, and vaccine manufacturers such as Merck & Co., GlaxoSmithKline, and Sanofi. Strategies include birth-dose vaccination, catch-up campaigns in schools, and screening of blood donations enforced by agencies like U.S. Food and Drug Administration and European Medicines Agency.

Treatment and Management

Antiviral therapy uses nucleos(t)ide analogues and interferon formulations to suppress replication and reduce disease progression; pivotal clinical trials and guidelines have been produced by American Association for the Study of Liver Diseases, European Association for the Study of the Liver, World Health Organization, Asian Pacific Association for the Study of the Liver, and national institutes including National Institutes of Health. Pharmaceutical developments and drug approvals have involved companies such as Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb, Roche, and regulatory review by Food and Drug Administration, European Medicines Agency, and national regulatory authorities. Liver transplantation and long-term care pathways are coordinated by transplant centers and professional societies like American Society of Transplantation and International Liver Transplantation Society.

Category:Viruses